LX-039 (2.5 mg/kg; PO and IV; single) exhibits excellent mouse pharmacokinetics, low clearance, high Cmax and oral exposure[1].
LX-039 (6.5 mg/kg, 20 mg/kg and 60 mg/kg; PO; daily for 21 days) inhibits tumor growth in a dose-dependent manner[1].
LX-039 (1 mg/kg; PO and IV; single) displays a moderate to low clearance (Cl) plus good oral bioavailability (F%) in both rat and dog[1].
Pharmacokinetic Parameters of LX-039 in CD-1 mouse[1].
| IV | PO (2.5 mg/kg) |
| Vd (L/kg) | 0.5 | |
| CL (mL/min/kg) | 1.4 | |
| Cmax (nM) | | 1873 |
| AUC0-24 (nM·h) | | 15329 |
| F (%) | | 60.1 |
Pharmacokinetic Parameters of LX-039 in SD rat and Beagle dog[1].
| SD Rat | Beagle Dog |
| Vd (L/kg, iv) | 2 | 0.42 |
| CL (mL/min/kg, iv) | 7.7 | 0.84 |
| C0, iv (nM), 1 mg/kg | 2610 | 12800 |
| AUC0-24, iv (nM·h), 1 mg/kg | 4820 | 43800 |
| Cmax, po (nM), 1 mg/kg | 381 | 2550 |
| AUC0-24, po (nM·h), 1 mg/kg | 2700 | 24200 |
| F (%) | 56 | 55 |